Ana Lacerda

1.3k total citations · 1 hit paper
18 papers, 502 citations indexed

About

Ana Lacerda is a scholar working on Neurology, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ana Lacerda has authored 18 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 8 papers in Pediatrics, Perinatology and Child Health and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ana Lacerda's work include Neuroblastoma Research and Treatments (9 papers), Childhood Cancer Survivors' Quality of Life (7 papers) and Ethics and Legal Issues in Pediatric Healthcare (6 papers). Ana Lacerda is often cited by papers focused on Neuroblastoma Research and Treatments (9 papers), Childhood Cancer Survivors' Quality of Life (7 papers) and Ethics and Legal Issues in Pediatric Healthcare (6 papers). Ana Lacerda collaborates with scholars based in Portugal, United Kingdom and Austria. Ana Lacerda's co-authors include Ruth Ladenstein, Victoria Castel, Andrew D.J. Pearson, Bárbara Gomes, Ellen Ruud, Geneviève Laureys, Paolo Bruzzi, Bruno De Bernardi, Jean Michon and Maja Beck‐Popovic and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Ana Lacerda

16 papers receiving 493 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Standards for Pediatric Palliative Care: From IMPaCCT to GO-PPaCS

2022 104 citations Franca Benini, Danai Papadatou et al. Journal of Pain and Symptom Management profile →

Peers

Countries citing papers authored by Ana Lacerda

Since Specialization

Citations

This map shows the geographic impact of Ana Lacerda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Lacerda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Lacerda more than expected).

Fields of papers citing papers by Ana Lacerda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Lacerda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Lacerda. The network helps show where Ana Lacerda may publish in the future.

Co-authorship network of co-authors of Ana Lacerda

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Lacerda. A scholar is included among the top collaborators of Ana Lacerda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Lacerda. Ana Lacerda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Perceptions of physicians caring for pediatric patients with cancer in Europe: insights into the use of palliative care, its timing, and barriers to early integration 2024 ·Frontiers in Oncology ·Ana Lacerda, (unknown), (unknown), Godwin Job, (unknown), Ulrike Leiss, (unknown), Katrin Scheinemann, Finella Craig, (unknown), Meenakshi Devidas, Justin N. Baker, Asya Agulnik, Michael J. McNeil	1
2	Aggressiveness of Care at the End of Life of Children Dying with Cancer in Public Hospitals—A Nationwide Retrospective Cohort Study 2024 ·Journal of Palliative Medicine ·Ana L. Cardoso, (unknown), Diogo Martins-Branco, Ana Lacerda, Bárbara Gomes, Sílvia Lopes	0
3	Embracing paediatric palliative care in paediatric oncology from diagnosis onwards 2023 ·Pediatric Blood & Cancer ·Ana Lacerda, (unknown), Benoît Dumont, Ulrike Leiss, (unknown), Katrin Scheinemann, Finella Craig	8
4	International Standards for Pediatric Palliative Care: From IMPaCCT to GO-PPaCS breakdown → 2022 ·Journal of Pain and Symptom Management ·Franca Benini, Danai Papadatou, (unknown), Finella Craig, Lucia De Zen, Julia Downing, Ross Drake, Stefan J. Friedrichsdorf, Daniel Garros, Luca Giacomelli, Ana Lacerda, Pierina Lazzarin, Sara Marceglia, Joan Marston, Mary Ann Muckaden, (unknown), Elvira Parravicini, (unknown), Joanne Wolfe	104
5	Utilização do Internamento Hospitalar em Portugal Continental por Crianças com Doenças Crónicas Complexas (2011 – 2015) 2019 ·Acta Médica Portuguesa ·Ana Lacerda, (unknown), (unknown), Sílvia Lopes	11
6	Aggressiveness of care at the end of life in children with cancer: A nationwide cohort study 2017 ·Annals of Oncology ·(unknown), Diogo Martins-Branco, Ana Lacerda, Bárbara Gomes, Sílvia Lopes	3
7	Trends in cause and place of death for children in Portugal (a European country with no Paediatric palliative care) during 1987–2011: a population-based study 2017 ·BMC Pediatrics ·Ana Lacerda, Bárbara Gomes	26
8	Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial. 2016 ·Journal of Clinical Oncology ·Ruth Ladenstein, Ulrike Pöetschger, Martin Elliott, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Mališ, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schrøeder, Ana Lacerda, Maja Beck‐Popovic, (unknown), Miklós Garami, Toby N. Trahair, Andrew D.J. Pearson, D. Couanet, (unknown)	1
9	A importância de cuidados paliativos em Pediatria 2013 ·SHILAP Revista de lepidopterología ·Ana Lacerda	0
10	The prognostic value of semi-quantitative 123I MIBG scintigraphy at diagnosis in high risk neuroblastoma: validation of the SIOPEN score method 2011 ·Pediatric Blood & Cancer ·Ruth Ladenstein, Ulrike Pöetschger, Ariane Boubaker, Zvi Bar‐Sever, (unknown), Anton Staudenherz, Maria Rita Castellani, (unknown), (unknown), Penelope Brock, Alberto Garaventa, Isaac Yaniv, Dominique Valteau‐Couanet, Victoria Castel, Ana Lacerda, Josef Mališ, Henrik Daa Schrøder, Roberto Luksch, Klaus Beiske, Valerie Lewington	9
11	The prognostic value of semi-quantitative ¹²³I mIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method. 2011 ·Journal of Clinical Oncology ·Valerie Lewington, Ulrike Pöetschger, Ariane Boubaker, Zvi Bar‐Sever, (unknown), Anton Staudenherz, Massimo Castellani, Bieke Lambert, (unknown), Penelope Brock, Alberto Garaventa, I. Yaniv, D. Couanet, Victoria Castel, Ana Lacerda, Josef Mališ, H. Schroeder, Roberto Luksch, Klaus Beiske, Ruth Ladenstein	8
12	Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. 2011 ·Journal of Clinical Oncology ·Ruth Ladenstein, Ulrike Pöetschger, (unknown), Penelope Brock, (unknown), I. Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Mališ, Walentyna Balwierz, Ellen Ruud, Per Kogner, H. Schroeder, Ana Lacerda, (unknown), (unknown), (unknown), (unknown), Andrew D.J. Pearson, (unknown)	26
13	Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. 2011 ·Journal of Clinical Oncology ·Ruth Ladenstein, Ulrike Pöetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Mališ, Walentyna Balwierz, Ellen Ruud, Per Kogner, (unknown), Ana Lacerda, (unknown), (unknown), Miklós Garami, Toby N. Trahair, (unknown), D. Couanet	33
14	Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study 2010 ·Journal of Clinical Oncology ·Ruth Ladenstein, Dominique Valteau‐Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Geneviève Laureys, Josef Mališ, Vassilios Papadakis, Ana Lacerda, Ellen Ruud, Per Kogner, Miklós Garami, Walentyna Balwierz, Henrik Schrøeder, Maja Beck‐Popovic, G. Schreier, David Machin, Ulrike Pötschger, Andrew D.J. Pearson	95
15	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification 2009 ·Journal of Clinical Oncology ·Bruno De Bernardi, Mary Gerrard, Luca Boni, Hervé Rubie, Adela Cañete, Andrea Di Cataldo, Victoria Castel, Ana Lacerda, Ruth Ladenstein, Ellen Ruud, Bénédicte Brichard, Jérôme Couturier, Caroline Ellershaw, Caroline Munzer, Paolo Bruzzi, Jean Michon, Andrew D.J. Pearson	91
16	Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group 2008 ·British Journal of Cancer ·Bruno De Bernardi, Véronique Mosseri, H Rubie, Victoria Castel, A.B.M. Foot, Ruth Ladenstein, Geneviève Laureys, Maja Beck‐Popovic, Ana Lacerda, Andrew D.J. Pearson, Jan de Kraker, Peter F. Ambros, Yann De Rycke, Massimo Conte, Paolo Bruzzi, Jean Michon	81
17	CGH evaluation of two de novo synchronous tumors in a child with a germline p53 mutation 2005 ·Pediatric Blood & Cancer ·Lúcia Roque, Ana Lacerda, Raquel Rodrigues, (unknown), (unknown), Carla Pinto	3
18	P73 EXPRESSION IN NEUROBLASTOMA: A ROLE IN THE BIOLOGY OF ADVANCED TUMORS? 2001 ·Pediatric Hematology and Oncology ·Paulo Matos, (unknown), (unknown), Ana Lacerda, António Gentil Martins, Maria Guida Boavida	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact